Highline Innovation Investment Partnership, LLC v. Biolert, LTD.

CourtDistrict Court, E.D. Texas
DecidedAugust 12, 2022
Docket4:21-cv-00615
StatusUnknown

This text of Highline Innovation Investment Partnership, LLC v. Biolert, LTD. (Highline Innovation Investment Partnership, LLC v. Biolert, LTD.) is published on Counsel Stack Legal Research, covering District Court, E.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Highline Innovation Investment Partnership, LLC v. Biolert, LTD., (E.D. Tex. 2022).

Opinion

United States District Court EASTERN DISTRICT OF TEXAS SHERMAN DIVISION

HIGHLINE INNOVATION § INVESTMENTS PARTNERSHIP, LLC, § § Plaintiff, § § Civil Action No. 4:21-CV-00615 § Judge Mazzant v. §

§ BIOLERT, LTD., GUY WILNAI, RUBEN § KUZNIECKY, URI KRAMER, and HEZY § SHALEV,

Defendants. MEMORANDUM OPINION AND ORDER Pending before the Court is Defendants Ruben Kuzkiecky’s, Guy Wilnai’s, and Hezy Shalev’s Consolidated Motion to Dismiss Under Federal Rules of Procedure 12(b)(6) and 9(b) and, in the alternative, Motion to Strike Plaintiff’s First Amended Complaint Under Federal Rules of Civil Procedure 12(f) and 15 (Dkt. #27). Having reviewed the motion, the responses, and the applicable law, the Court finds that the motion should be DENIED. BACKGROUND This contractual dispute arises out of the international acquisition of intellectual property rights pertaining to seizure alert technology. Defendant Biolert, Ltd (“Biolert”) is an Israeli entity that developed the “Biolert System,” “the industry’s first actionable seizure alert system that uses off-the-shelf wearable technology—making the system accessible to anyone living with epilepsy” (Dkt. #20 ¶ 10). Defendants Guy Wilnai, Ruben Kuzniecky, Uri Kramer, and Hezy Shalev are alleged to collectively be the majority shareholders of Biolert (Dkt. #20 ¶ 13). In early 2018, Biolert began holding discussions with prospective Australian investors about merging Biolert into a publicly-listed entity on the Australian Securities Exchange (Dkt. #20 at ¶ 15). One of those investors was Plaintiff Highline Innovation Investments Partnership, LLC (“Highline”). To encourage investor participation, Biolert prepared a PowerPoint presentation (the “June 2018 Presentation”) representing “that Biolert’s proprietary software algorithm utilized ‘Machine learning/Artificial Intelligence (AI)’ for personalized analytics, false alarm[, and] seizure

detection” (Dkt. #20 ¶ 20). The use of AI technology—or “machine learning”—was incredibly attractive to investors because it allowed the software’s algorithm to be “adaptive so its behavior can change (by deriving new and important insights) over time based on new data obtained from users of the software” (Dkt. #20 ¶ 21). More specifically: [B]y gathering user movement data which would then be analyzed by machine learning, Biolert was confirming to investors that its software was able to better recognize and adapt to user movements that were not epileptic seizures (thereby decreasing false alarms) and movements that were epileptic seizures (thereby increasing seizure detection accuracy)

(Dkt. #20 ¶ 22). Without this AI technology, the Biolert System’s extremely low rate of false alarms—which was represented as less than .01 percent per day—would not have been possible (Dkt. #20 ¶ 26). The Presentation also represented that Biolert had conducted a study with the Epilepsy Foundation of Texas (the “EFTX”).1 The study showed that the Biolert system had a ninety-five percent success rate in accurately detecting seizures, which—according to the June 2018 Presentation—earned Biolert a national endorsement from the EFTX. On December 1, 2018, the American Epilepsy Society (“AES”) hosted its annual conference in New Orleans, LA. The AES conference, which is touted as the largest of its kind, “showcases the latest research, products, services and technology related to epilepsy and other neurology-related disorders to investors and members of the epilepsy community” (Dkt. #20

1 EFTX “is one of the largest of the fifty state affiliates of the Epilepsy Foundation, which is the nationwide epilepsy umbrella organization that provides community services, public education, advocacy, seizure first aid training, and research funding for more than 3.4 million individuals in the United States that suffer from epilepsy” (Dkt. #20 ¶ 23). at ¶ 28). Here, Biolert again prepared a presentation (the “AES Presentation”) for potential investors (Dkt. #20 at ¶ 28). In the AES presentation, Biolert showcased its use of “Machine learning / Artificial Intelligence (‘AI’) for personalized analytics, false alarm & seizure detection” (Dkt. #20 at ¶ 29). Biolert also again represented that the Biolert System had a seizure detection

accuracy rate of ninety-five percent (Dkt. #20 at ¶ 28). In January 2019, Biolert and Highline began negotiations for Highline to license or acquire the Biolert System (Dkt. #20 at ¶¶ 32–33). During negotiations, Highline was provided with, among other things, the June 2018 Presentation and the AES Presentation (Dkt. #20 at ¶ 33). Subsequently, on February 11, 2019, Highline entered a contract with Biolert (the “Term Sheet”) (Dkt. #20 at ¶ 35). Under the Term Sheet, the parties’ agreed that Highline would acquire Biolert’s patent rights and technology rights, defined as nonpublic information, trade secret, know-how, and confidential information, in exchange for certain consideration (Dkt. #27 at p. 5). However, Highline alleges that it eventually learned Biolert’s claims in the June 2018 Presentation and AES Presentation concerning the accuracy and ingenuity of the Biolert System

were misrepresentations (Dkt. #20 at ¶ 38). For instance, Highline alleges it discovered the Biolert System “never utilized artificial intelligence, machine learning, or any adaptive algorithms” (Dkt. #20 at ¶ 39). Consequently, Highline alerted Biolert of its intention not to proceed with the acquisition of Biolert’s intellectual property assets and formally demanded the return of consideration paid by Highline under the Term Sheet (Dkt. #20 at ¶ 43). On November 16, 2021, Highline sued Defendants for the following causes of action: common law fraud; fraud by non-disclosure; fraud in the inducement; lifting the corporate veil; negligent misrepresentation; various violations of the Texas Deceptive Trade Practices Act (“DTPA”); and breach of the implied warranty of merchantability (Dkt. #20). On November 30, 2021, Defendants filed the present motion (Dkt. #27). On December 14, 2021, Highline filed its response (Dkt. # 31). On December 21, 2021, Defendants filed a reply (Dkt. #32). LEGAL STANDARDS I. Federal Rule of Civil Procedure 12(b)(6)

The Federal Rules of Civil Procedure require that each claim in a complaint include a “short and plain statement . . . showing that the pleader is entitled to relief.” FED. R. CIV. P. 8(a)(2). Each claim must include enough factual allegations “to raise a right to relief above the speculative level.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007). A Rule 12(b)(6) motion allows a party to move for dismissal of an action when the complaint fails to state a claim upon which relief can be granted. FED. R. CIV. P. 12(b)(6). When considering a motion to dismiss under Rule 12(b)(6), the Court must accept as true all well-pleaded facts in the plaintiff’s complaint and view those facts in the light most favorable to the plaintiff. Bowlby v. City of Aberdeen, 681 F.3d 215, 219 (5th Cir. 2012). The Court may consider “the complaint, any documents attached to the complaint, and any documents attached to the motion to

dismiss that are central to the claim and referenced by the complaint.” Lone Star Fund V (U.S.), L.P. v. Barclays Bank PLC, 594 F.3d 383, 387 (5th Cir. 2010).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Melder v. Morris
27 F.3d 1097 (Fifth Circuit, 1994)
Lyn-Lea Travel Corp. v. American Airlines, Inc.
283 F.3d 282 (Fifth Circuit, 2002)
Herrmann Holdings Ltd. v. Lucent Technologies Inc.
302 F.3d 552 (Fifth Circuit, 2002)
Smith v. EMC Corporation
393 F.3d 590 (Fifth Circuit, 2004)
Jones v. Robinson Property Group, L.P.
427 F.3d 987 (Fifth Circuit, 2005)
Texas Clinical Labs, Inc. v. Leavitt
535 F.3d 397 (Fifth Circuit, 2008)
United States Ex Rel. Grubbs v. Kanneganti
565 F.3d 180 (Fifth Circuit, 2009)
Morgan v. Gusman
335 F. App'x 466 (Fifth Circuit, 2009)
Gonzalez v. Kay
577 F.3d 600 (Fifth Circuit, 2009)
Lone Star Fund v (U.S.), L.P. v. Barclays Bank PLC
594 F.3d 383 (Fifth Circuit, 2010)
Foman v. Davis
371 U.S. 178 (Supreme Court, 1962)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Robert J. Boreri v. Fiat S.P.A.
763 F.2d 17 (First Circuit, 1985)
Bowlby v. City of Aberdeen, Miss.
681 F.3d 215 (Fifth Circuit, 2012)
Federal Deposit Insurance v. Niblo
821 F. Supp. 441 (N.D. Texas, 1993)
G. Richard Goins Construction Co. v. S.B. McLaughlin Associates,Inc.
930 S.W.2d 124 (Court of Appeals of Texas, 1996)

Cite This Page — Counsel Stack

Bluebook (online)
Highline Innovation Investment Partnership, LLC v. Biolert, LTD., Counsel Stack Legal Research, https://law.counselstack.com/opinion/highline-innovation-investment-partnership-llc-v-biolert-ltd-txed-2022.